InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2025)

InMed Pharmaceuticals' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $208737.0 for Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $208737.0 in Q4 2025; TTM through Dec 2025 was $208737.0, a N/A change from a year earlier, with the FY2025 full-year figure at $208737.0, down 31.74% from the prior year.
• Asset Writedowns and Impairment was little changed at $208737.0 in Q4 2025 per INM's latest filing, from $208737.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $576772.0 in Q3 2022 and bottomed at -$551687.0 in Q4 2022.
• The 4-year median for Asset Writedowns and Impairment is $131702.0 (2023), against an average of $96257.6.
• Across the five-year window, Asset Writedowns and Impairment sank 83.89% in 2023 and soared 392.21% in 2025, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at -$551687.0 in 2022, then surged by 130.9% to $170474.0 in 2023, then sank by 75.12% to $42408.0 in 2024, then jumped by 392.21% to $208737.0 in 2025.
• Per Business Quant, the three latest INM Asset Writedowns and Impairment figures stand at $208737.0 (Q4 2025), $208737.0 (Q2 2025), and $42408.0 (Q2 2024).